DiRECT Just Showed 5-Year Remission Is Real. It’s Still Not a Cure.
The DiRECT trial — the landmark structured weight-management trial in Type 2 diabetes — just published its 5-year follow-up, showing that remission is possible and durable when weight loss is maintained. At 1 year, 46% of participants in the intervention group were in remission, per the DiRECT primary trial report in The Lancet. At 2 […]
Novo’s Next GLP-1 Just Hit 89% A1c Target
Novo Nordisk’s next-generation triple-agonist zenagamtide just hit 89.1% A1c target attainment in phase 2 — one of the highest rates ever reported for a Type 2 diabetes therapy, per the ADA 2026 Scientific Sessions coverage and the Novo Nordisk pipeline announcement. In adults with Type 2 diabetes, the highest dose produced 14.6% body-weight loss and […]
Strength Training Plus Cardio Just Cut Diabetes Risk
A new meta-analysis published in Sports Medicine and reported by News-Medical.net found that combining strength training with aerobic exercise cuts Type 2 diabetes risk more than either modality alone. Across 35 studies and over 90,000 participants, the combination reduced Type 2 diabetes risk by 17–40% depending on dose, with the strongest effect at 150+ minutes […]
An Oral GLP-1 Just Hit 89% A1c Target
A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo. The results, presented this week […]
Retatrutide Just Got Renal Data
Eli Lilly’s retatrutide — the triple-hormone receptor agonist that already made headlines in 2026 for its 2.0% A1c reduction and 16.8% body-weight loss in Type 2 diabetes — just published renal outcomes data in The New England Journal of Medicine. The ORBIT trial evaluated retatrutide in adults with Type 2 diabetes and chronic kidney disease, […]
The ADA’s Own Definition of Remission Just Hit a Wall
The American Diabetes Association’s own consensus definition of type 2 diabetes remission — HbA1c < 6.5% for at least 3 months, off all glucose-lowering medication — just turned five years old, and a growing body of 2026 evidence shows that the vast majority of patients on mainstream diabetes drugs never get close to meeting it. […]
Stanford Just Found Why GLP-1s Don’t Work for 1 in 10 People
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach […]
Generic Dapagliflozin Just Got Approved.
The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a daily SGLT2 inhibitor to lower […]
Lilly’s Oral GLP-1 Just Hit Its Numbers. It’s Still Not Reversal.
Eli Lilly’s oral GLP-1, orforglipron, just hit its primary endpoint in the first Phase 3 trial designed to support an FDA submission. The Lilly press release announced results from ACHIEVE-1, published in The New England Journal of Medicine, showing a 1.3%–1.6% A1c reduction and 6.8%–7.9% weight loss in adults with early Type 2 diabetes on […]
ADA 2026 Made Multimorbidity the Headline.
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers in The Lancet on June […]